F18-FDG

Phase 2Small molecule

UUniversity Health Network, Toronto

F18-FDG is one of 68 small molecule programs targeting Pancreatic Neuroendocrine Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Neuroendocrine TumorActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Pancreatic Neuroendocrine TumorPreclinical

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Viread

Gilead

Preclinical

1 2

Sovaldi

Gilead

Preclinical

1 3

Coreg

Akero Therapeutics

Preclinical

2 4

F18-FDG

UUniversity Health Network, Toronto

Phase 2

1 5

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 6

Opdivo

Bristol-Myers Squibb

Preclinical

2 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Statin

1 10

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/AActive, not recruiting

Pancreatic Neuroendocrine Tumor

NCT04804371

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT05009979·8 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

Active, not recruiting·UUniversity Health Network, Toronto·N/A·NCT04804371·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for F18-FDG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — F18-FDG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for F18-FDG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Health Network, Toronto

F18-FDG

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Pancreatic Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News